SCYNEXIS INC(SCYX)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
SCYNEXIS INC (SCYX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SCYX at 14.2/100 on a 32-signal composite quality model, placing it at rank #2,868 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), SCYNEXIS INC reports quarterly revenue of $235.0K, net income of $7.4M. Top institutional holders of SCYX by reported 13-F value include GREAT POINT PARTNERS, Squadron Capital Management, Propel Bio Management, based on the most recent SEC filings. SCYX trades on the Nasdaq exchange and files with the SEC under CIK 1178253. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SCYX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SCYNEXIS INC directly from SEC EDGAR.
AI Quality Score
14.2/100
AI Rank
#2,868
Revenue
$235.0K
Net Income
$7.4M
SCYX key financials by period
SCYNEXIS INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$20.6M
$-8.6M
-78.0%
FY 2024
10-K
$3.7M
$-21.3M
—
FY 2023
10-K
$140.1M
$67.0M
51.8%
FY 2022
10-K
$5.1M
$-62.8M
—
FY 2021
10-K
$13.2M
$-32.9M
—
FY 2019
10-K
$121.0K
$-53.7M
—
Institutions holding SCYX
Institutional investors reporting a position in SCYNEXIS INC on SEC Form 13F.
